-
Not Synced
Chris Anderson. Welcome, Bill Gates.
-
Not Synced
Bill Gates: Thank you.
-
Not Synced
CA: All right. It's great
to have you here, Bill.
-
Not Synced
You know, we had a TED conversation
-
Not Synced
about three months ago
about this pandemic,
-
Not Synced
and back then I think fewer than --
-
Not Synced
I think that was the end of March --
-
Not Synced
Back then, fewer than
a thousand people in the US had died,
-
Not Synced
and fewer than 20,000 worldwide.
-
Not Synced
I mean, the numbers now are,
like, 128,000 dead in the US
-
Not Synced
and more than half a million worldwide.
-
Not Synced
in three months.
-
Not Synced
In three months.
-
Not Synced
What is your diagnosis of what is possible
for the rest of this year?
-
Not Synced
You look at a lot of models.
-
Not Synced
What do you think best
and worst case scenarios might be?
-
Not Synced
BG: Well, the range of scenarios, sadly,
-
Not Synced
is quite large, including that,
-
Not Synced
as we get into the fall,
-
Not Synced
we could have death rates
-
Not Synced
that rival the worst of what we had
in the April time period.
-
Not Synced
If you get a lot of young people infected,
-
Not Synced
eventually they will infect
old people again,
-
Not Synced
and so you'll get into the nursing homes,
-
Not Synced
the homeless shelters,
-
Not Synced
the places where we've had
a lot of our deaths.
-
Not Synced
The innovation track,
which probably we will touch on --
-
Not Synced
diagnostics, therapeutics, vaccines --
-
Not Synced
there's good progress there,
-
Not Synced
but nothing that would
fundamentally alter the fact
-
Not Synced
that this fall in the United States
could be quite bad,
-
Not Synced
and that's worse than
I would have expected a month ago,
-
Not Synced
the degree to which we're back
at high mobility,
-
Not Synced
not wearing masks,
-
Not Synced
and now the virus actually
has gotten into a lot of cities
-
Not Synced
that it hadn't been in before
-
Not Synced
in a significant way,
-
Not Synced
so it's going to be a challenge.
-
Not Synced
There's no case where we get
much below the current death rate,
-
Not Synced
which is about 500 deaths a day,
-
Not Synced
but there's a significant risk
we'd go back up
-
Not Synced
to the even 2,000 a day
that we had before,
-
Not Synced
because we don't have the distancing,
-
Not Synced
the behavior change,
-
Not Synced
to the degree that we had
in April and May,
-
Not Synced
and we know this virus
is somewhat seasonal,
-
Not Synced
so that the force of infection,
-
Not Synced
both through temperature, humidity,
more time indoors,
-
Not Synced
will be worse as we get into the fall.
-
Not Synced
CA: So there are scenarios
where in the US,
-
Not Synced
like, if you extrapolate
those numbers forward,
-
Not Synced
we end up with, what,
-
Not Synced
more than a quarter of a million deaths,
-
Not Synced
perchance, even this year
if we're not careful,
-
Not Synced
and worldwide I guess the death toll
could by the end of the year
-
Not Synced
be well into the millions, with an s.
-
Not Synced
Is there evidence that the hotter
temperatures of the summer
-
Not Synced
actually have been helping us?
-
Not Synced
BG: They're not absolutely sure,
-
Not Synced
but certainly the ?? model
definitely wanted to use the season,
-
Not Synced
including temperature and humidity,
-
Not Synced
to try and explain why May
wasn't worse than it was.
-
Not Synced
And so as we came out
and the mobility numbers got higher,
-
Not Synced
the models expected more infections
and deaths to come out of that,
-
Not Synced
and the model kept wanting to say,
-
Not Synced
"But I need to use this seasonality
-
Not Synced
to match why May wasn't worse,
-
Not Synced
why June wasn't worse than it was."
-
Not Synced
And we see in the Southern Hemisphere,
-
Not Synced
you know, Brazil,
-
Not Synced
which is the opposite season,
-
Not Synced
all of South America
is having a huge epidemic.
-
Not Synced
South Africa is having
a very fast-growing epidemic.
-
Not Synced
Fortunately, Australia and New Zealand,
-
Not Synced
the last countries
in the Southern Hemisphere,
-
Not Synced
are at really tiny case counts,
-
Not Synced
and so although they have
to keep knocking it down,
-
Not Synced
they're talking about, oh,
we have 10 cases,
-
Not Synced
that's a big deal,
let's go get rid of that.
-
Not Synced
So they're one of these amazing countries
-
Not Synced
that got the numbers so low
-
Not Synced
that test, quarantine and trace
-
Not Synced
is working to get them,
-
Not Synced
keep them at very near zero.
-
Not Synced
CA: Aided perhaps a bit
by being easier to isolate
-
Not Synced
and by less density,
less population density,
-
Not Synced
but nonetheless smart policies down there.
-
Not Synced
BG: Yeah. Everything is so exponential
that a little bit of good work
-
Not Synced
goes a long ways.
-
Not Synced
It's not a linear game.
-
Not Synced
Contact tracing, if you have
the number of cases we have in the US,
-
Not Synced
it's super-important to do,
-
Not Synced
but it won't get you back down to zero.
-
Not Synced
It'll help you be down,
-
Not Synced
but it's too overwhelming.
-
Not Synced
CA: OK, so in May and June in the US,
-
Not Synced
the numbers were actually slightly better
than some of the models predicted,
-
Not Synced
and it's hypothesized that that might be
partly because of the warmer weather.
-
Not Synced
Now we're seeing, really,
would you describe it
-
Not Synced
as really quite alarming upticks
in case rates in the US?
-
Not Synced
BG: That's right.
-
Not Synced
In, say, the New York area,
-
Not Synced
the cases continue to go down somewhat,
-
Not Synced
but in other parts of the country,
-
Not Synced
primarily the South right now,
-
Not Synced
you have increases
that are offsetting that,
-
Not Synced
and you have testing
positive rates in young people
-
Not Synced
that are actually higher
-
Not Synced
than what we saw even
in some of the tougher areas,
-
Not Synced
and so clearly younger people
have come out of mobility
-
Not Synced
more than older people
have increased their mobility,
-
Not Synced
so the age structure
-
Not Synced
is right now very young, but
because of multigenerational households,
-
Not Synced
people work in nursing care homes,
-
Not Synced
unfortunately that will work its way back,
-
Not Synced
both the time lag and the transmission
back up into the elderly,
-
Not Synced
will start to push the death rate back up,
-
Not Synced
which it is down,
-
Not Synced
way down from 2,000
to around 500 right now.
-
Not Synced
CA: And is that partly because
there's a three-week lag
-
Not Synced
between case numbers and fatality numbers?
-
Not Synced
And also, perhaps, partly because
-
Not Synced
there have been
some effective interventions
-
Not Synced
and we're actually seeing the possibility
-
Not Synced
that the overall fatality rate
is actually falling a bit
-
Not Synced
now that we've gained
some extra knowledge?
-
Not Synced
BG: Yeah, certainly
your fatality rate is always lower
-
Not Synced
when you're not overloaded,
-
Not Synced
and so Italy when they were overloaded,
-
Not Synced
Spain, even New York at the start,
-
Not Synced
certainly China,
-
Not Synced
there you weren't even able
to provide the basics,
-
Not Synced
the oxygen and things.
-
Not Synced
A study that our foundation
funded in the UK
-
Not Synced
found the only thing
other than remdesivir
-
Not Synced
that is a proven therapeutic,
-
Not Synced
which is the dexamethasone,
-
Not Synced
that for serious patients
-
Not Synced
is about a 20 percent death reduction,
-
Not Synced
and there's still quite
a pipeline of those things.
-
Not Synced
You know, hydroxychloroquine
never established positive data,
-
Not Synced
so that's pretty much done.
-
Not Synced
There's still a few trials ongoing,
-
Not Synced
but the list of things being tried,
-
Not Synced
including eventually
?? antibodies,
-
Not Synced
we will have some additional
tools for the fall.
-
Not Synced
And so when you talk about death rates,
-
Not Synced
the good news is some
innovation we already have
-
Not Synced
and we will have more
-
Not Synced
even in the fall.
-
Not Synced
We should start to have
monoclonal antibodies,
-
Not Synced
which is the single therapeutic
that I'm most excited about.
-
Not Synced
CA: I'll actually ask you to tell me
a bit more about that in one sec,
-
Not Synced
but just putting the pieces
together on death rates:
-
Not Synced
so in a well-functioning health system,
-
Not Synced
so take the US when places
aren't overcrowded,
-
Not Synced
what do you think
-
Not Synced
the current fatality numbers
are approximately going forward,
-
Not Synced
like as a percentage of total cases?
-
Not Synced
Are we below one percent, perhaps?
-
Not Synced
BG: If you found every case, yes,
-
Not Synced
you're well below one percent.
-
Not Synced
People argue, you know, 0.4, 0.5.
-
Not Synced
By the time you bring in
the never symptomatics,
-
Not Synced
it probably is below 0.5,
-
Not Synced
and that's good news.
-
Not Synced
This disease could have been
a five percent disease.
-
Not Synced
The transmission dynamics of this disease
-
Not Synced
are more difficult
than even the experts predicted.
-
Not Synced
The amount of pre-symptomatic
and never symptomatic spread,
-
Not Synced
and the fact that it's not coughing,
-
Not Synced
where you would kind of notice,
hey, I'm coughing.
-
Not Synced
Most respiratory diseases make you cough.
-
Not Synced
This one, in its early stages,
it's not coughing,
-
Not Synced
it's singing, laughing, talking,
-
Not Synced
actually still particularly
for the super-spreaders,
-
Not Synced
people with very high viral loads,
-
Not Synced
causes that spread,
-
Not Synced
and that's pretty novel,
-
Not Synced
and so even experts have to say,
wow, this caught us by surprise.
-
Not Synced
The amount of asymptomatic spread
-
Not Synced
and the fact that there's not
a coughing element
-
Not Synced
is not a major piece like the flu or TB.
-
Not Synced
CA: Yeah, that is devilish cunning
-
Not Synced
by the virus.
-
Not Synced
I mean, how much is
that non-symptomatic transmission
-
Not Synced
as a percentage of total transmission?
-
Not Synced
I've heard numbers it could be
as much as half of all transmissions
-
Not Synced
are basically pre-symptomatic.
-
Not Synced
BG: Yeah, if you count pre-symptomatics,
-
Not Synced
then most of the studies show
that's like at 40 percent,
-
Not Synced
and we also have never symptomatics.
-
Not Synced
The amount of virus you get
in your upper respiratory area
-
Not Synced
is somewhat disconnected.
-
Not Synced
Some people will have a lot here
and very little in their lungs,
-
Not Synced
and what you get in your lungs
-
Not Synced
causes the really bad symptoms,
-
Not Synced
and other organs,
-
Not Synced
but mostly the lungs,
-
Not Synced
and so that's when you seek treatment.
-
Not Synced
And so the worst case
in terms of spreading
-
Not Synced
is somebody who's got a lot
in the upper respiratory tract
-
Not Synced
but almost none in their lungs,
-
Not Synced
so they're not care-seeking.
-
Not Synced
CA: Right.
-
Not Synced
And so if you add in the never symptomatic
-
Not Synced
to the pre-symptomatic,
-
Not Synced
do you get above 50 percent
of the transmission
-
Not Synced
is actually from non-symptomatic people?
-
Not Synced
BG: Yeah, transmission
is harder to measure.
-
Not Synced
You know, we see certain
hotspots and things,
-
Not Synced
but that's a huge question
with the vaccine:
-
Not Synced
will it, besides avoiding
you getting sick,
-
Not Synced
which is what the trial will test,
-
Not Synced
will it also stop you
from being a transmitter?
-
Not Synced
CA: So that vaccine,
-
Not Synced
it's such an important question,
let's come on to that,
-
Not Synced
but before we go there,
-
Not Synced
any other surprises
in the last couple months
-
Not Synced
that we've learned about this virus
-
Not Synced
that really impact how
we should respond to it?
-
Not Synced
BG: We're still not able to characterize
who the super-spreaders are
-
Not Synced
in terms of what that profile is,
-
Not Synced
and we may never.
-
Not Synced
That may just be quite random.
-
Not Synced
If you could identify them,
-
Not Synced
they're responsible
for the majority of transmission,
-
Not Synced
a few people who have
very high viral loads.
-
Not Synced
But sadly, we haven't figured that out.
-
Not Synced
This mode of transmission,
-
Not Synced
if you're in a room and nobody talks,
-
Not Synced
there's way less transmission.
-
Not Synced
That's partly why,
although planes can transmit,
-
Not Synced
it's less than you would expect
just in terms of time proximity measures,
-
Not Synced
because unlike, say,
a choir or a restaurant,
-
Not Synced
you're not exhaling in loud talking
-
Not Synced
quite as much as in
other indoor environments.
-
Not Synced
CA: What do you think about the ethics
of someone who would go on a plane
-
Not Synced
and refuse to wear a mask?
-
Not Synced
BG: If they own the plane,
that would be fine.
-
Not Synced
If there's other people on the plane,
-
Not Synced
that would be endangering
those other people.
-
Not Synced
CA: Early on in the pandemic,
-
Not Synced
the WHO did not advise
that people wear masks.
-
Not Synced
They were worried about taking them away
from frontline medical providers.
-
Not Synced
In retrospect, was that
a terrible mistake that they made?
-
Not Synced
BG: Yes.
-
Not Synced
All the experts feel bad
-
Not Synced
that the value of masks,
-
Not Synced
which ties back somewhat
to the asymptomatics,
-
Not Synced
if people were very symptomatic,
-
Not Synced
like in Ebola,
-
Not Synced
then you know it and you isolate,
-
Not Synced
and so you don't have
a need for a mask-like thing.
-
Not Synced
The value of masks,
-
Not Synced
the fact that the medical masks
was a different supply chain
-
Not Synced
than the normal masks,
-
Not Synced
the fact you could scale up
the normal masks so well,
-
Not Synced
the fact that it would stop
that pre-symptomatic,
-
Not Synced
never symptomatic transmission,
-
Not Synced
it's a mistake,
-
Not Synced
but it's not a conspiracy,
-
Not Synced
it's something that we now know more.
-
Not Synced
And even now, our error bars
on the benefit of masks
-
Not Synced
are higher than we'd like to admit,
-
Not Synced
but it's a significant benefit.
-
Not Synced
CA: All right, I'm going to come in
with some questions
-
Not Synced
from the community.
-
Not Synced
Let's pull them up there.
-
Not Synced
Jim Pitofsky: "Do you think reopening
efforts in the US have been premature,
-
Not Synced
and if so how far should the US go
to responsibly confront this pandemic?"
-
Not Synced
BG: Well, the question
of how you make tradeoffs
-
Not Synced
between the benefits, say,
of going to school
-
Not Synced
versus the risk of people getting sick
because they go to school,
-
Not Synced
those are very tough questions
-
Not Synced
that I don't think any single person
-
Not Synced
can say, "I will tell you
how to make all these tradeoffs."
-
Not Synced
The understanding of
where you have transmission,
-
Not Synced
and the fact that young people
do get infected
-
Not Synced
and are part of the multi-generational
transmission chain,
-
Not Synced
we should get that out.
-
Not Synced
If you just look at the health aspect,
-
Not Synced
we have opened up too liberally.
-
Not Synced
Now, opening up in terms of mental health
-
Not Synced
and seeking normal health things
-
Not Synced
like vaccines and other care,
-
Not Synced
there are benefits.
-
Not Synced
I think some of our opening up
-
Not Synced
has created more risk than benefit.
-
Not Synced
Opening the bars up
as quickly as they did,
-
Not Synced
is that critical for mental health?
-
Not Synced
Maybe not.
-
Not Synced
So I don't think we've been
as tasteful about opening up
-
Not Synced
as I'm sure, as we study it,
-
Not Synced
that we'll realize some things
we shouldn't have opened up as fast,
-
Not Synced
but then you have something like school,
-
Not Synced
where even sitting here today,
-
Not Synced
the exact plan, say,
for inner city schools for the fall,
-
Not Synced
I wouldn't have a black-and-white view
-
Not Synced
on the relative tradeoffs involved there.
-
Not Synced
There are huge benefits
-
Not Synced
to letting those kids go to school,
-
Not Synced
and how do you weigh the risk?
-
Not Synced
If you're in a city
-
Not Synced
without many cases,
-
Not Synced
I would say probably the benefit is there.
-
Not Synced
Now that means that
you could get surprised.
-
Not Synced
The cases could show up,
and then you'd have to change that,
-
Not Synced
which is not easy.
-
Not Synced
But I think around the US
there will be places
-
Not Synced
where that won't be a good tradeoff.
-
Not Synced
So almost any dimension and inequity,
-
Not Synced
this disease has made worse:
-
Not Synced
job type, internet connection,
-
Not Synced
ability of your school
to do online learning.
-
Not Synced
White collar workers,
-
Not Synced
people are embarrassed to admit it,
-
Not Synced
some of them are more productive
-
Not Synced
and enjoying the flexibility
that the at-home thing has created,
-
Not Synced
and that feels terrible
-
Not Synced
when you know lots of people
are suffering in many ways,
-
Not Synced
including their kids not going to school.
-
Not Synced
CA: Indeed. Let's have the next question.
-
Not Synced
"For us in Rwanda,
-
Not Synced
early policy interventions
have made the difference.
-
Not Synced
At this point, what policy interventions
do you suggest for the US now?"
-
Not Synced
Bill, I dream of the day
where you are appointed
-
Not Synced
the coronavirus czar
-
Not Synced
with authority to actually
speak to the public.
-
Not Synced
What would you do?
-
Not Synced
BG: The innovation tools
-
Not Synced
are where I and the foundation
probably has the most expertise.
-
Not Synced
Clearly some of the policies
on opening up have been too generous,
-
Not Synced
but I think everybody
-
Not Synced
could engage in that.
-
Not Synced
We need leadership
-
Not Synced
in terms of admitting
-
Not Synced
that we've still got a huge problem here,
-
Not Synced
and not turning that
into almost a political thing
-
Not Synced
of, oh, isn't it brilliant what we did.
-
Not Synced
No, it's not brilliant,
-
Not Synced
but there's many people,
-
Not Synced
including the experts,
-
Not Synced
where there's a lot
they didn't understand,
-
Not Synced
and everybody wishes a week earlier
whatever action they took,
-
Not Synced
they'd taken that a week earlier.
-
Not Synced
The innovation tools,
-
Not Synced
that's where the foundation's work
-
Not Synced
on antibodies, vaccines,
-
Not Synced
we have deep expertise,
-
Not Synced
and it's outside of the private sector,
-
Not Synced
and so we have kind of a neutral ability
to work with all the governments
-
Not Synced
and the companies to pick.
-
Not Synced
Particularly when you're doing
break-even products,
-
Not Synced
which one should get the resources.
-
Not Synced
There's no market signal for that.
-
Not Synced
Experts have to say, OK,
this antibody deserves the manufacturing.
-
Not Synced
This vaccine deserves the manufacturing.
-
Not Synced
Because, we have very limited
manufacturing for both of those things,
-
Not Synced
and it'll be cross-company,
-
Not Synced
which never happens in the normal case,
-
Not Synced
where one company invents it
-
Not Synced
and then you're using
the manufacturing plants
-
Not Synced
of many companies
-
Not Synced
to get maximum scale of the best choice.
-
Not Synced
So I would be coordinating those things,
-
Not Synced
but we need a leader
who keeps us up to date,
-
Not Synced
is realistic,
-
Not Synced
and shows us the right behavior,
-
Not Synced
as well as driving the innovation track.
-
Not Synced
CA: I mean, you have to yourself
be a master diplomat
-
Not Synced
in how you talk about this stuff.
-
Not Synced
So I appreciate, almost,
the discomfort here,
-
Not Synced
but you talk regularly with Anthony Fauci,
-
Not Synced
who is a wise voice on this
by most people's opinion.
-
Not Synced
But to what extent is he just hamstrung?
-
Not Synced
He's not allowed to play the full role
-
Not Synced
that he could play in the circumstance.
-
Not Synced
BG: Dr. Fauci has emerged,
-
Not Synced
where he was allowed to have some airtime,
-
Not Synced
and even though he was stating
things that are realistic,
-
Not Synced
his prestige has stuck.
-
Not Synced
He can speak out in that way.
-
Not Synced
Typically, the CDC would be
the primary voice here.
-
Not Synced
It's not absolutely necessary,
-
Not Synced
but in previous health crises,
-
Not Synced
you let the experts inside the CDC
-
Not Synced
be that voice.
-
Not Synced
They're trained to do these things,
-
Not Synced
and so it is a bit unusual here
-
Not Synced
how much we've had to rely on Fauci
-
Not Synced
as opposed to the CDC.
-
Not Synced
It should be Fauci,
who is a brilliant researcher,
-
Not Synced
so experienced, particularly in vaccines,
-
Not Synced
in some ways he has become,
taking the broad advice
-
Not Synced
that is the epidemiology advice
-
Not Synced
and explaining it in the right way,
-
Not Synced
where he'll admit,
-
Not Synced
"OK, we may have a rebound here,
-
Not Synced
and this is why we need
to behave that way."
-
Not Synced
But it's fantastic that his voice
has been allowed to come through.
-
Not Synced
CA: Sometimes.
-
Not Synced
Let's have the next question.
-
Not Synced
Nina Gregory: "How are you
and your foundation
-
Not Synced
addressing the ethical questions
about which countries
-
Not Synced
get the vaccine first,
-
Not Synced
assuming you find one?"
-
Not Synced
And maybe, Bill, use this as a moment
-
Not Synced
to just talk about where
the quest for the vaccine is
-
Not Synced
and what are just some of the key things
we should all be thinking about
-
Not Synced
as we track the news on this.
-
Not Synced
BG: There's three vaccines that are,
-
Not Synced
if they work, are the earliest:
-
Not Synced
the Moderna, which unfortunately
won't scale very easily,
-
Not Synced
so if that works, it'll be mostly
a US-targeted thing;
-
Not Synced
then you have the AstraZeneca,
which comes from Oxford;
-
Not Synced
and the Johnson & Johnson.
-
Not Synced
Those are the three early ones,
-
Not Synced
and we have animal data
-
Not Synced
that looks potentially good,
-
Not Synced
but not definitive,
-
Not Synced
particularly will it work in the elderly,
-
Not Synced
and we'll have human data
over the next several months.
-
Not Synced
Those three will be gated by
the safety and efficacy trial.
-
Not Synced
That is, we'll be able
to manufacture those,
-
Not Synced
although not as much as we want.
-
Not Synced
We'll be able to manufacture those
before the end of the year.
-
Not Synced
Whether the Phase 3 will succeed,
-
Not Synced
and whether it'll complete
before the end of the year,
-
Not Synced
I wouldn't be that optimistic about.
-
Not Synced
Phase 3 is where you need
to really look at all the safety profile
-
Not Synced
and efficacy,
-
Not Synced
but those will get started.
-
Not Synced
And then there's four or five vaccines
-
Not Synced
that use different approaches
-
Not Synced
that are maybe three
or four months behind that:
-
Not Synced
Novavax, Sanofi, Merck.
-
Not Synced
And so we're funding factory capacity
for a lot of these --
-
Not Synced
some complex negotiations
are taking place right now on this --
-
Not Synced
to get factories that will be dedicated
to the poorer countries,
-
Not Synced
what's called low- and middle-income.
-
Not Synced
And the very scalable constructs
-
Not Synced
that include AstraZeneca
and Johnson & Johnson,
-
Not Synced
we'll focus on those,
-
Not Synced
the ones that are inexpensive
-
Not Synced
and you can build a single factory
to make 600 million doses.
-
Not Synced
So a number of the vaccine constructs
-
Not Synced
are potential.
-
Not Synced
I don't see anything
before the end of the year.
-
Not Synced
That's really the best case,
-
Not Synced
and it's down to a few constructs now,
-
Not Synced
which typically you have
high failure rates.
-
Not Synced
CA: Bill, is the case
-
Not Synced
that you and your foundation
weren't in the picture here
-
Not Synced
that market dynamics would likely
lead to a situation
-
Not Synced
where as soon as a promising
vaccine candidate emerged,
-
Not Synced
the richer countries
would basically snap up,
-
Not Synced
gobble up all available initial supply --
-
Not Synced
it just takes a while
to manufacture these --
-
Not Synced
and there would be nothing
for the poorer countries,
-
Not Synced
but that what effectively you're doing,
-
Not Synced
by giving manufacturing guarantees
-
Not Synced
and capability to some
of these candidates,
-
Not Synced
you're making it possible that
at least some of the early vaccine units
-
Not Synced
will go to poorer countries?
-
Not Synced
Is that correct?
-
Not Synced
BG: Well, it's not just us, but yes,
-
Not Synced
we're in the central role there
-
Not Synced
along with a group we created called CEPI,
-
Not Synced
Coalition for Epidemic Preparedness,
-
Not Synced
and the European leaders agree with this.
-
Not Synced
Now we have the expertise
to look at each of the constructs
-
Not Synced
and say, OK, where is there
a factory in the world
-
Not Synced
that has capacity that can build that?
-
Not Synced
Which one should we put
the early money into?
-
Not Synced
What should the milestones be
-
Not Synced
where we'll shift the money
over to a different one?
-
Not Synced
Because the kind of private sector people
-
Not Synced
who really understand that stuff,
-
Not Synced
some of them work for us,
-
Not Synced
and we're a trusted party on these things,
-
Not Synced
we get to coordinate a lot,
particularly the manufacturing piece.
-
Not Synced
Usually, you'd expect the US
-
Not Synced
to think of this as
a global problem and be involved.
-
Not Synced
So far, no activity
on that front has taken place.
-
Not Synced
I am talking to people in the Congress
and the Administration
-
Not Synced
about when the next
relief bill comes along
-
Not Synced
that maybe one percent of that
-
Not Synced
could go for the tools
-
Not Synced
to help the entire world.
-
Not Synced
And so it's possible,
-
Not Synced
but it's unfortunate,
-
Not Synced
and the vacuum here
-
Not Synced
the world is not that used to
-
Not Synced
and a lot of people are stepping in,
-
Not Synced
including our foundation,
-
Not Synced
to try and have a strategy,
-
Not Synced
including for the poorer countries
-
Not Synced
who will suffer a high percentage
of the deaths and negative effects,
-
Not Synced
including their health systems
being overwhelmed.
-
Not Synced
Most of the deaths will be
in developing countries,
-
Not Synced
despite the huge deaths we've seen
in Europe and the US.
-
Not Synced
CA: I mean, I wish I could be
a fly on the wall and hearing
-
Not Synced
you and Melinda talk about this,
-
Not Synced
because of all of
the ethical crimes, let's say,
-
Not Synced
executed by leaders
who should know better,
-
Not Synced
I mean, it's one thing
to not model mask-wearing,
-
Not Synced
but to not play a role
-
Not Synced
in helping the world when faced
with a common enemy,
-
Not Synced
respond as one humanity
-
Not Synced
and instead catalyze a really unseemly
scramble between nations
-
Not Synced
to fight for vaccines, for example.
-
Not Synced
That just seems that surely history
is going to judge that harshly.
-
Not Synced
That is just sickening.
-
Not Synced
Isn't it? Am I missing something?
-
Not Synced
BG: Well, it's not quite
as black and white as that.
-
Not Synced
The US has put more money out
-
Not Synced
to fund the basic research
on these vaccines
-
Not Synced
than any country by far,
-
Not Synced
and that research is not restricted.
-
Not Synced
There's not, like, some royalty
that says, "Hey, if you take our money,
-
Not Synced
you have to pay the US a royalty."
-
Not Synced
They do, to the degree they fund research,
-
Not Synced
it's for everybody.
-
Not Synced
To the degree they fund factories,
it's just for the US.
-
Not Synced
The thing that makes this tough is that
in every other global health problem,
-
Not Synced
the US totally leads smallpox eradication,
-
Not Synced
the US is totally the leader
on polio eradication
-
Not Synced
with key partners -- CDC, WHO,
Rotary, UNICEF, our foundation.
-
Not Synced
So the world, and on HIV,
-
Not Synced
what under President Bush's leadership,
but it was very bipartisan,
-
Not Synced
this thing called PEPFAR was unbelievable.
-
Not Synced
That has saved tens of millions of lives.
-
Not Synced
And so it's that the world
always expected the US
-
Not Synced
to at least be at the head of the table,
-
Not Synced
financially, strategy, OK, how do you
get these factories for the world,
-
Not Synced
even if it's just to avoid the infection
coming back to the US
-
Not Synced
or to have the global economy working,
-
Not Synced
which is good for US jobs
-
Not Synced
to have demand outside the US.
-
Not Synced
And so the world is kind of,
there's all this uncertainty
-
Not Synced
about which thing will work,
-
Not Synced
and there's, OK, who is in charge here?
-
Not Synced
And so the worst thing,
-
Not Synced
the withdrawal from WHO,
-
Not Synced
that is a difficulty
-
Not Synced
that hopefully will
get remedied at some point,
-
Not Synced
because we need that coordination
-
Not Synced
through WHO.
-
Not Synced
CA: Let's take another question.
-
Not Synced
Ali Kashani: "Are there any
particularly successful models
-
Not Synced
of handling the pandemic
that you have seen around the world?"
-
Not Synced
BG: Well, it's fascinating that,
besides early action,
-
Not Synced
there are definitely things where
you take people who have tested positive
-
Not Synced
and you monitor their ??,
-
Not Synced
which is a oxygen saturation
level in their blood,
-
Not Synced
which is a very cheap detector,
-
Not Synced
and then you know to get them
to the hospitals fairly early.
-
Not Synced
Weirdly, patients don't know
things are about to get severe.
-
Not Synced
It's an interesting physiological reason
but I won't get into.
-
Not Synced
And so Germany has
a quite a low case fatality rate
-
Not Synced
that they've done through
that type of monitoring.
-
Not Synced
And then, of course,
once you get into facilities,
-
Not Synced
we've learned that the ventilator
actually, although extremely well-meaning,
-
Not Synced
was actually overused
and used in the wrong mode
-
Not Synced
in those early days.
-
Not Synced
So the health, the doctors
-
Not Synced
are way smarter about treatment today.
-
Not Synced
Most of that I would say is global.
-
Not Synced
Using this ??
as an early indicator,
-
Not Synced
that'll probably catch on broadly,
-
Not Synced
but Germany was a pioneer there.
-
Not Synced
And now, of course, dexamethasone,
-
Not Synced
fortunately, it's cheap, it's oral,
-
Not Synced
we can ramp up manufacture.
-
Not Synced
That'll go global as well.
-
Not Synced
CA: Bill, I want to ask you something about what it's been like for you personally through this whole process? Because, weirdly, even though your passion and good intent on this topic seems completely bloody obvious to anyone who has spent a moment with you, there are these crazy conspiracy theories out there about you. I just checked in with a company called Zignal that monitors social media spaces. They say that, to date, I think on Facebook alone, more than four million posts have taken place that associate you with some kind of conspiracy theory around the virus.